Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

CoreWeaves quarterly results beat expectations and its raised full-year outlook sparked relief and short-squeeze hopes. Traders remain divided over whether stronger growth and customer demand can outweigh heavy spending, debt and financing risks, with many questioning whether the post-earnings gains will hold.

Nvidia shares are under pressure amid Jensen Huangs acknowledged relationship with a woman alleged to have ties to Chinese intelligence and the boards investigation into potential disclosure, security, and export-control risks. Traders are split between fears of further fallout or Huangs departure and views that the selloff is an overreaction that creates a buying opportunity, with the companys underlying AI-chip business still seen as strong.

Netlists Q3 results are driving attention, with higher sales and operating income supported in part by Samsung license-fee revenue. Traders are largely upbeat about the stronger financial picture but are debating whether it can sustain the share-price move, while some had hoped for additional updates on SK hynix or a Nasdaq listing.

Amprius quarterly results are driving attention: revenue growth and raised full-year guidance were offset by an EPS miss and negative adjusted EBITDA, prompting a sharp selloff despite many traders calling the report strong. The community is split between viewing the drop as a reaction to profitability concerns and blaming broader market weakness or short-selling.

Rigettis quarterly results missed expectations, prompting concern about weak commercial revenue and ongoing losses. Traders are split between skepticism that its quantum technology can translate into a viable business and optimism about its 108-qubit fidelity milestone and long-term potential.

Q3 earnings are the main focus, with traders noting a beat and stronger 2026 revenue guidance but questioning the stocks negative reaction despite the results. Some also see the Japanese Synspective multi-launch agreement as a future catalyst not reflected in the quarter.

Nebius is drawing attention ahead of its quarterly report, with traders treating CoreWeaves strong results and raised guidance as a read-through for AI-cloud demand while debating whether NBIS can turn demand into revenue without financing or capacity-execution problems. Bulls expect a rebound across neoclouds, while skeptics point to the recent selloff and ongoing concerns about capital needs and whether good results are already priced in.

LightPaths fiscal first-quarter report is driving attention, with strong revenue growth, a record backlog and expanding gross margins drawing praise. Reactions are mixed: some traders see the results as validation of the growth story, while others point to weak after-hours trading and want clearer evidence of execution and outlook from management.

The scheduled Nov. 22 FDA decision on Capricors Duchenne muscular dystrophy treatment Deramiocel dominates discussion, with traders weighing the HOPE-3 upper-limb results and recent AHA recognition against concerns raised during the advisory-panel review. The quarterly update is viewed as secondary; some investors were disappointed by the lack of new detail on FDA discussions, while approval optimism and bearish skepticism fuel debate around the stocks sharp swings.

Kuras Q3 update is drawing attention for accelerating KOMZIFTI uptake, with prescriptions growing faster than new patient startsa sign some traders interpret as improving patient retention and launch traction. The reaction is broadly encouraged by the commercial progress and cash runway, though competition in AML and skepticism about whether early uptake will translate into sustained growth remain part of the debate.